Brought to you by 
EyeTech Pharmaceuticals licenses Isis' patents
09 May 2005
Executive Summary
EyeTech Pharmaceuticals (focuses on diseases of the eye) has licensed nonexclusive worldwide rights to certain ophthalmic patents from Isis Pharmaceuticals (small-molecule RNA drugs).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
EyeTech Pharmaceuticals licenses Isis' patents
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice